Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review

Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported;...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jiahao, Cai, Meiqin, Li, Wensheng, Hou, Bo, He, Haiyong, Ling, Cong, Huang, Tengchao, Liu, Huijiao, Guo, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838606/
https://www.ncbi.nlm.nih.gov/pubmed/27296952
http://dx.doi.org/10.3727/096504016X14612603423511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838606/
https://www.ncbi.nlm.nih.gov/pubmed/27296952
http://dx.doi.org/10.3727/096504016X14612603423511

Ejemplares similares